Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

Why did the Fed cut interest rates today? How will the Fed rate cut affect mortgages? What caused Cracker Barrel’s customer decline? Why is Nvidia banned from selling AI chips in China? How did Trump’s UK visit impact US-UK tech deal? Why did Ben & Jerry’s co-founder quit? What’s behind the surge in AI startup funding?

Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

cnbc.com/2025/09/17/eli-lilly-obesity-pill-beats-novo-nordisk-drug-in-diabetes-trial-.html

Eli Lilly on Wednesday said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes.
The late-stage study comes as Eli Lilly's pill inches closer to becoming another needle-free…

This story appeared on cnbc.com, 2025-09-17 15:23:46.801000.